Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$70.66M+1353.63%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark L. Baum
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 373
- Beta
- 0.24
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 1.96
Financials
Revenue
$70.66M+1353.6%Net Income
$-17.27MEBITDA
$-11.01MFree Cash Flow
$-9.56MEPS (diluted)
$-0.46Shares Outstanding (diluted)
37.35M+177.3%Operating Expenses
$61.37MCash & Debt
$83.89MReturn of Capital
$0.00Revenue by Segment (annual)
$272.30MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $272.30M | $-5.14M | $-0.14 |
| 2024 | $199.61M | $-17.48M | $-0.49 |
| 2023 | $130.19M | $-24.41M | $-0.75 |
| 2022 | $88.59M | $-14.09M | $-0.51 |
| 2021 | $72.48M | $-18.01M | $-0.69 |
| 2020 | $48.87M | $-3.36M | $-0.13 |
| 2019 | $51.16M | $168.0K | $0.01 |
| 2018 | $41.37M | $14.63M | $0.67 |
| 2017 | $26.77M | $-11.98M | $-0.60 |
| 2016 | $19.94M | $-19.09M | $-1.50 |
| 2015 | $9.72M | $-15.90M | $-1.66 |
| 2014 | $1.66M | $-10.12M | $-1.11 |
| 2013 | $10.0K | $-7.64M | $-0.88 |
| 2012 | $100.0K | $-5.38M | $-1.24 |
Valuation
HROWhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·6d ago·Neutral
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific abstracts featuring data from across its ophthalmic portfolio will be presented at two major eyecare meetings: American Academy of Optometry's (AAOpt) Annual meeting taking place September 30 – October 3, 2026, in Anaheim…
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·55d ago·Neutral
Harrow Q2 Earnings Call Highlights Harrow NASDAQ: HROW reported second-quarter revenue of $70.7 million, up 11% from a year earlier and about 60% sequentially, as the ophthalmic pharmaceutical company said it entered the second half of 2026 with stronger demand across several products, improved pricing and expanded commercial infrastructure.
View source ↗ - Newszacks.com·56d ago·Negative
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates Harrow (HROW) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.24 per share a year ago.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $0.16 per share
Typical surprise -79.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.46 vs $-0.18miss
- Mon, May 11$-0.74 vs $-0.43miss
- Mon, Mar 2$0.18 vs $0.40miss
- Mon, Nov 10$0.03 vs $0.22miss
- Mon, Aug 11$0.14 vs $0.01beat
- Thu, May 8$-0.50 vs $0.02miss
Estimates and results for HROW via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HROW officers and directors.
- Bought
- $3.1m
- Sold
- $12.4m
16 trades
18 trades
- Shojaei Amirsold
- Graves Adrienne Lbought
- Silvernail Lauren Pbought
- Baum Mark Lbought
- Boll Andrew R.bought
- Opaleye Management Inc.sold
- Opaleye Management Inc.sold
- Opaleye Management Inc.sold
66 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HROW.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.